On July 15, Elevance Health fell 3.28% in pre-market trading, trading at $409.75/share, with turnover of $436,300. The decline comes despite the company reporting Q2 results that significantly exceeded Wall Street expectations.

Elevance Health posted Q2 adjusted EPS of $7.45, beating the consensus estimate of $6.21 by approximately 20%, while revenue of $49.826 billion topped the $48.693 billion estimate. The company also raised its full-year adjusted EPS guidance to at least $27, above both its prior target of $26.75 and the FactSet consensus of $26.87.

However, Q2 adjusted EPS still declined 15.72% year-over-year from $8.84. Additionally, the stock had surged 5.25% in pre-market trading the prior session as multiple investment banks raised price targets ahead of the report, suggesting the beat was partially priced in. The broader managed health care sector is also under pressure, with UnitedHealth down 1.89%, Centene down 4.37%, and Humana down 1.66%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)